Press Releases

BOSTON , Dec. 14, 2021 (GLOBE NEWSWIRE) -- Lead investigators from clinical trials evaluating eprenetapopt in patients with  TP53  mutant MDS or AML presented positive, updated data at the 2021 ASH Annual Meeting. All studies evaluated the tolerability and efficacy of  Aprea Therapeutics, Inc. 
60% relapse free survival at 1 year post-transplant 79% overall survival at 1 year post-transplant Median overall survival of 20.6 months BOSTON , Dec. 13, 2021 (GLOBE NEWSWIRE) --   Aprea Therapeutics, Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing